title: Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.
abstract: We studied the prognostic significance of plasmablastic (PB) multiple myeloma (MM) in Eastern Cooperative Oncology Group Phase III trial E9486. Two reviewers independently reviewed 453 cases. They agreed on 37 PB (8.2%) cases and 416 non-PB cases, achieving an 85% concordance (P < .0001). These PB cases had significantly lower hemoglobin and serum albumin levels, higher calcium and beta 2-microglobuin levels, and higher percentage BM plasma cells (PC) by immunofluorescence. They had higher bone marrow PC labeling indices, higher serum soluble interleukin-6 receptor (sIL-6R) levels, and a higher probability of ras mutations. Three treatment regimens were used: vincristine, bis-chloro-ethyl nitrosourea (BCNU) melphalan, cyclophosphamide, and prednisone (VBMCP) alone; VBMCP with added cyclophosphamide (HiCy); or recombinant interferon alpha 2 (rIFNalpha2). Although the numbers are low, patients with PB had a significantly lower response rate versus non-PB MM when treated with VBMCP (treated, 47.1% v nontreated, 66.5% [P = .015]). Patients with nonresponding PB had a significantly higher progression rate than non-PB cases (30.6% v 11.8% [P < .0001]), especially with VBMCP alone (35.3% v 15.8% [P = .002]), and with added HiCy (37.5% v 9.8% [P < .0001]), but not with added rIFNalpha2. Event-free and overall survival of PB MM was shorter (median years, 1.1 v 2.7 and 1.9 v 3.7, respectively [P < .0001 for both]). In multivariate analysis, PB classification was also highly prognostic. There is no survival difference between the patients who were classified as PB by both reviewers versus patients classified as PB by only one reviewer. We conclude that PB MM is a discrete entity associated with more aggressive disease and shortened survival. Tumor cell ras mutations and increased sIL-6R may contribute to a higher proliferation rate and reduced survival. There were significant improvements in response and progression with the addition of HiCy and rIFNalpha2 to VBMCP, but the numbers were small and improved survival could not be shown.
authors.affiliation: Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: P R
authors.initials: PR
authors.lastname: Greipp
authors.forename: T
authors.initials: T
authors.lastname: Leong
authors.forename: J M
authors.initials: JM
authors.lastname: Bennett
authors.forename: J P
authors.initials: JP
authors.lastname: Gaillard
authors.forename: B
authors.initials: B
authors.lastname: Klein
authors.forename: J A
authors.initials: JA
authors.lastname: Stewart
authors.forename: M M
authors.initials: MM
authors.lastname: Oken
authors.forename: N E
authors.initials: NE
authors.lastname: Kay
authors.forename: B
authors.initials: B
authors.lastname: Van Ness
authors.forename: R A
authors.initials: RA
authors.lastname: Kyle
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D011905:Genes, ras; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology*; D010950:Plasma Cells / Q000473:pathology*; D011379:Prognosis; D019947:Receptors, Interleukin-6 / Q000096:biosynthesis
chemical_list: D019947:Receptors, Interleukin-6